Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-008-9943-9
Annals of Surgical Oncology 15:2129-2136 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nakamura, Y.
Right arrow Articles by Mori, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, Y.
Right arrow Articles by Mori, M.

Original Article

PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer

Yoshito Nakamura, MD, PhD1,4, Fumiaki Tanaka, MD, PhD1,3, Yasuji Yoshikawa, MD, PhD2, Koshi Mimori, MD, PhD1,3, Hiroshi Inoue, MD, PhD1,3, Katsuhiko Yanaga, MD, PhD4 and Masaki Mori, MD, PhD1,3

1 Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumibaru, Beppu 874-0838, Japan
2 Department of Pathology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumibaru, Beppu 874-0838, Japan
3 Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama, Japan
4 Department of Surgery, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, Japan

Correspondence: Address correspondence and reprint requests to: Masaki Mori; E-mail: mmori{at}tsurumi.beppu.kyushu-u.ac.jp

Purpose: Human platelet-derived growth factor BB (PDGF-BB) is thought to be involved in human malignancies. Its overexpression has been reported in some human tumors. However, its expression in colorectal cancer has not been studied. We thus investigated the clinicopathological and biological significance of PDGF-BB gene expression in human colorectal cancer.

Experimental Design: Using real-time reverse transcription-PCR, we evaluated PDGF-BB expression status and correlated data with clinicopathological parameters in 60 patients with colorectal cancer. Additionally, we established a colorectal cancer cell line expressing PDGF-BB and investigated its effects on cell invasion and proliferation.

Results: The incidence of vascular invasion was significantly greater in patients expressing PDGF-BB at a high level than in those at a low level (P <.05). Patients with high PDGF-BB expression had a significantly poorer survival rate than those with low PDGF-BB expression (P <.05). A multivariate analysis demonstrated that PDGF-BB expression was an independent prognostic factor. We demonstrated in vitro that cells transduced with PDGF-BB showed greater invasiveness (P < .05) and migration (P < .001) than did mock transduced cells. In a xenograft study, cells transduced with PDGF-BB had higher proliferation rates than mock transfected cells.

Conclusion: PDGF-BB expression may be a new prognostic indicator for patients with colorectal cancer.

Key Words: PDGF-BB • Colorectal cancer • Vascular invasion • Prognosis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.